Prospects for the use of ATR inhibitors to treat cancer

Jill M. Wagner; Scott H. Kaufmann

doi:10.3390/ph3051311

Prospects for the use of ATR inhibitors to treat cancer

Jill M. Wagner, Scott H. Kaufmann

Oncology

Research output: Contribution to journal › Review article › peer-review

44 Scopus citations

Abstract

ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

Original language	English (US)
Pages (from-to)	1311-1334
Number of pages	24
Journal	Pharmaceuticals
Volume	3
Issue number	5
DOIs	https://doi.org/10.3390/ph3051311
State	Published - 2010

Keywords

ATM
ATR
Chemotherapy
Chk1
Replication checkpoint

ASJC Scopus subject areas

Molecular Medicine
Pharmaceutical Science
Drug Discovery

Access to Document

10.3390/ph3051311

Cite this

@article{f20a6f6f632e4d30979de334fdd588df,

title = "Prospects for the use of ATR inhibitors to treat cancer",

abstract = "ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.",

keywords = "ATM, ATR, Chemotherapy, Chk1, Replication checkpoint",

author = "Wagner, {Jill M.} and Kaufmann, {Scott H.}",

year = "2010",

doi = "10.3390/ph3051311",

language = "English (US)",

volume = "3",

pages = "1311--1334",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",

number = "5",

}

TY - JOUR

T1 - Prospects for the use of ATR inhibitors to treat cancer

AU - Wagner, Jill M.

AU - Kaufmann, Scott H.

PY - 2010

Y1 - 2010

N2 - ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

AB - ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.

KW - ATM

KW - ATR

KW - Chemotherapy

KW - Chk1

KW - Replication checkpoint

UR - http://www.scopus.com/inward/record.url?scp=77954938500&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=77954938500&partnerID=8YFLogxK

U2 - 10.3390/ph3051311

DO - 10.3390/ph3051311

M3 - Review article

AN - SCOPUS:77954938500

SN - 1424-8247

VL - 3

SP - 1311

EP - 1334

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 5

ER -

Prospects for the use of ATR inhibitors to treat cancer

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this